Order Careers Contact Us Sign in Adaptive Biotechnologies Order Careers
Contact Us Sign in Immune Profiling Platform Platform OverviewPublications
Products & Services LIFE SCIENCES RESEARCHimmunoSEQ®CLINICAL
DIAGNOSTICSclonoSEQ®PipelineDRUG DISCOVERYCellular TherapyVaccines
PARTNERSHIPS Cancer Cellular TherapyAntigen MapBiopharma PartnershipsStrategic
Collaborators About Us Our StoryCultureCareersNewsroomContact Us About Us
Newsroom Press News Features Events Contact Media Relations TOP PRESS RELEASES
01/04/2019 Adaptive Biotechnologies to Enter Into Worldwide Collaboration and
License Agreement with Genentech to Develop Personalized Cellular Therapies
for the Treatment of Cancer 01/03/2019 Adaptive Biotechnologies to Present at
the 37th Annual J.P. Morgan Healthcare Conference 09/28/2018 FDA Grants De
Novo Designation for Adaptive Biotechnologies’ clonoSEQ Assay to Detect and
Monitor Minimal Residual Disease (MRD) in Patients with Multiple Myeloma and
Acute Lymphoblastic Leukemia LATEST PRESS RELEASES 01/04/2019 Adaptive
Biotechnologies to Enter Into Worldwide Collaboration and License Agreement
with Genentech to Develop Personalized Cellular Therapies for the Treatment of
Cancer 01/03/2019 Adaptive Biotechnologies to Present at the 37th Annual J.P.
Morgan Healthcare Conference 12/01/2018 Adaptive Biotechnologies and
Collaborators to Present 28 Studies at ASH 2018 That Support the Use of the
clonoSEQ® Assay to Detect and Monitor Minimal Residual Disease in Patients
with Blood Cancers 09/28/2018 A New Study Published in the Journal Blood
Demonstrates that Measuring Minimal Residual Disease Negativity Using Adaptive
Biotechnologies’ Next-Generation Sequencing Platform is a Major Predictive
Indicator in Multiple Myeloma 09/28/2018 FDA Grants De Novo Designation for
Adaptive Biotechnologies’ clonoSEQ Assay to Detect and Monitor Minimal
Residual Disease (MRD) in Patients with Multiple Myeloma and Acute
Lymphoblastic Leukemia 05/29/2018 Adaptive Biotechnologies Announces a
Collaboration With Sanofi to use Adaptive’s clonoSEQ® Assay to Measure Minimal
Residual Disease in Active and Future Isatuximab Multiple Myeloma Trials
04/02/2018 FDA Approves First Therapy for Patients With MRD-Positive ALL
02/13/2018 Adaptive Biotechnologies Appoints Veteran Molecular Diagnostics
Executive Michael Pellini, MD, to Board of Directors 01/04/2018 Adaptive
Biotechnologies Announces Partnership with Microsoft to Decode the Human
Immune System to Improve the Diagnosis of Disease 1 2 … 15 Next TOP NEWS
FEATURES 01/04/2019 Genentech: A New Age for Neoantigens 01/03/2019 Microsoft
Blog: Every immune system has a story to tell; the key is knowing how to
listen 05/09/2018 T Cell Receptor Sequencing IDs Aggressive Lymphoma Subtype
LATEST NEWS FEATURES 01/04/2019 Genentech: A New Age for Neoantigens
01/03/2019 Microsoft Blog: Every immune system has a story to tell; the key is
knowing how to listen 05/09/2018 T Cell Receptor Sequencing IDs Aggressive
Lymphoma Subtype 11/13/2017 Adaptive Ranks #107 in Deloitte’s Technology Fast
500 06/12/2017 EY’s Pacific NW Entrepreneur of the Year Award winners revealed
for 2017 06/06/2017 Starting a Business, Q13 Fox News Interview with Kaci
Aitchison 05/22/2017 Seattle Children’s Brings First-of-its-kind Precision
Medicine Clinical Trial to Inflammatory Bowel Disease, Bone Marrow Transplant
Patients 04/06/2017 Adaptive Biotechnologies Identifies Signature of Viral
Infection in Immune Repertoire 03/04/2017 Fred Hutch study discovers rare set
of cells that are highly effective at fighting cancer 1 2 … 11 Next TOP EVENTS
01/03/2019 J.P. Morgan Healthcare Conference 2019 12/01/2018 ASH 2018 LATEST
EVENTS 01/03/2019 J.P. Morgan Healthcare Conference 2019 12/01/2018 ASH 2018
11/07/2018 SITC 2018 11/01/2018 AMP Annual Meeting 2018 09/13/2018 3rd Annual
Rational Combinations 360° 09/12/2018 SOHO Annual Meeting 2018 09/02/2018 5th
European Congress of Immunology 2018 08/09/2018 2018 Genomics 2.0 Summit
06/24/2018 Cell Symposia: Translational Immune Metabolism d-none d-sm-block 1
2 3 Next Contact media relations phone (917) 912-7195 email
media@adaptivebiotech.com Corporate/Research (855) 466-8667 Diagnostics (888)
522-8988 Immune Profiling PlatformPlatform Overview Publications Products &
ServicesLIFE SCIENCES RESEARCH immunoSEQ® CLINICAL DIAGNOSTICS clonoSEQ®
Pipeline DRUG DISCOVERY Cellular Therapy Vaccines PartnershipsCancer Cellular
Therapy Antigen Map Biopharma Partnerships Strategic Collaborators About UsOur
Story Culture Careers News & Events Contact Us © Adaptive Biotechnologies. All
Rights Reserved. Terms of Use Online Privacy Policy Privacy Shield Policy
HIPAA Policy Code of Conduct Patents & Trademarks Licenses